Healthy
+1
A Study of LY3437943 in Participants With Impaired and Normal Liver Function
Sponsored by Eli Lilly and Company
About this trial
Last updated 2 years ago
Study ID
18531
Status
Recruiting
Type
Interventional
Phase
Phase 1
Placebo
No
Accepting
18 to 85 Years
All
Trial Timing
Ended a year ago
What is this trial about?
The main purpose of this study is to measure how much of LY3437943 gets into the bloodstream
and how long it takes the body to eliminate it in participants with mild, moderate and severe
impaired liver function compared to healthy participants with normal liver function. The
safety and tolerability of LY3437943 will also be evaluated. The study may last up to 9 weeks
for each participant including the screening period.
What are the participation requirements?
Inclusion Criteria
- Have a body mass index within the range 19.0 to 42.0 kilograms per meter squared (kg/m²), inclusive
- Healthy or various degrees of hepatic impairment depending on the study group
Exclusion Criteria
- Have or are anticipating an organ transplant within the next 6 months
- Requires needle evacuation of ascites fluid more than 2 times per month
- Have had variceal bleeding within 3 months of check-in, unless the participant has undergone a successful banding procedure; in that case, may check-in from 1 month after the banding procedure